Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ACE | P12821 | 2/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19626677 | 0.83 | OPRM1 (0.43) | CXCR4HTR2CMEN1KMT2AACE | |
| SCHEMBL13587827 | 0.81 | CXCR4 (0.41) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL7309721 | 0.80 | CXCR4 (0.40) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL14558528 | 0.80 | CXCR4 (0.40) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL15701682 | 0.78 | HRH3 (0.45) | CXCR4OPRM1HRH3OPRL1 | |
| SCHEMBL15701679 | 0.77 | CXCR4 (0.46) | CXCR4HTR2CMEN1KMT2AACE | |
| SCHEMBL28303172 | 0.77 | MEN1 (0.45) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL29538245 | 0.77 | MEN1 (0.45) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL14603017 | 0.76 | CXCR4 (0.39) | CXCR4MEN1KMT2AACEOPRM1 | |
| SCHEMBL15701683 | 0.74 | OPRM1 (0.46) | CXCR4HTR2COPRM1HRH3OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF QUEENSLAND | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130581-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN | OPRL1, CRH, OPRK1 | CXCR4 341/4885HTR2C 147/4885MEN1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.